Constantine Tam
Professor, Director of Haematology
Peter MacCallum Cancer Centre / St Vincent's Hospital / University of Melbourne · Melbourne, Australia
Led the AIM study (ibrutinib + venetoclax in MCL, 7-year follow-up data) and TARMAC (CAR-T + ibrutinib bridging in relapsed MCL).
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.
Blood advances · Feb 24, 2026
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis.
Current medical research and opinion · Dec 1, 2025
Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma.
Leukemia & lymphoma · Dec 1, 2025
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
The Lancet. Oncology · Feb 1, 2025
Nodal T-Cell Lymphoma Transdifferentiated from Mantle Cell Lymphoma with Epstein-Barr Virus Infection.
Pathobiology : journal of immunopathology, molecular and cellular biology · Jan 1, 2025
Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia.
Blood · Dec 26, 2024
Ibrutinib and venetoclax combination therapy for mantle cell lymphoma: are two better than one?
Expert review of hematology · Dec 1, 2024
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
Blood · Aug 22, 2024
BTK inhibitors in CLL: second-generation drugs and beyond.
Blood advances · May 14, 2024
CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study.
Blood · Feb 22, 2024